Under intense cost and efficiency pressures, the pharmaceutical industry has increasingly outsourced clinical trial work to contract research organizations (CROs). Over the past decade this has led to unprecedented consolidation in the CRO sector. Dozens of mergers and acquisitions (M&A) have created global “one-stop” research giants, but also raised questions about cost, quality, and competition. In 2021 alone, a record 50 CRO M&A deals closed – nearly double the prior year’s total. Mega-deals involving industry leaders accelerated the trend. Meanwhile, smaller “bolt-on” acquisitions continue, targeting specialized capabilities (e.g. data analytics firms, patient-recruitment networks, trial site organizations, and advanced-therapy specialists).
Read the full article: CRO Consolidation: How Mergers Impact Clinical Trials //
Source: https://intuitionlabs.ai/articles/cro-consolidation-clinical-trials-impact